Chemomab Therapeutics (STU:2QV) EPS (Basic): €-0.96 (TTM As of Mar. 2026)


STU:2QV Chemomab Therapeutics Ltd STU:2QV
34 GF Score
Price €2.98
View Full Analysis

What is Chemomab Therapeutics EPS (Basic)?

Chemomab Therapeutics STU:2QV 34 EPS (Basic) is €-0.96 as of Mar. 2026. GuruFocus rates STU:2QV with a GF Score™ of 34/100.

Chemomab Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.21. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.96.

Chemomab Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.21. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.96.

Chemomab Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was €-0.21. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.96.

During the past 3 years, the average EPS without NRI Growth Rate was 47.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 9.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Chemomab Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 47.00% per year. The lowest was -56.20% per year. And the median was 13.40% per year.

Chemomab Therapeutics  (STU:2QV) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Chemomab Therapeutics EPS (Basic) Related Terms

Chemomab Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Chemomab Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemomab Therapeutics EPS (Basic) Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -4.25 -9.14 -7.56 -2.98 -1.23

Chemomab Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.52 -0.28 -0.27 -0.21 -0.21
STU:2QV
34GF Score
Chemomab Therapeutics Ltd STU:2QV
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chemomab Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Chemomab Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-7.682-0)/6.378
=-1.20

Chemomab Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.534-0)/7.979
=-0.19

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.96 mean?
Chemomab Therapeutics (STU:2QV) has a EPS (Basic) of €-0.96 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Chemomab Therapeutics and its competitors.
Is Chemomab Therapeutics' EPS (Basic) too high?
Chemomab Therapeutics' current EPS (Basic) is €-0.96. Overall, Chemomab Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Chemomab Therapeutics' EPS (Basic) compare to HCWB and MTVA?
Chemomab Therapeutics' EPS (Basic) of €-0.96 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Chemomab Therapeutics and its competitors. Chemomab Therapeutics's current EPS (Basic) is €-0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemomab Therapeutics stock overvalued right now?
Chemomab Therapeutics (STU:2QV) has a current EPS (Basic) of €-0.96. The current EPS (Basic) is €-0.96. Chemomab Therapeutics' overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Chemomab Therapeutics (STU:2QV), the current EPS (Basic) is €-0.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chemomab Therapeutics Business Description

Other Exchanges CMMB:USA
Address 10 Habarzel Street, 10th Floor, Building C, Tel Aviv, ISR, 6158101
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
34GF Score

Get the complete analysis for STU:2QV

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.98
Price